Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.

摘要: Abstract Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after vaccination with Oxford-AstraZeneca vaccine ChAdOx1-S Denmark Norway to compare them observed general populations. Design Population based cohort study. Setting Nationwide healthcare registers Norway. Participants All people aged 18-65 years who received a from 9 February 2021 11 March 2021. The populations (2016-18) (2018-19) served as comparator cohorts. Main outcome measures Observed day hospital contacts for incident arterial events, venous thromboembolism, thrombocytopenia/coagulation disorders, bleeding among vaccinated compared expected rates, on national age sex specific background two countries. Results cohorts comprised 148 792 (median 45 years, 80% women) 132 472 44 78% women), their dose ChAdOx1-S. Among 281 264 ChAdOx1-S, standardised morbidity ratio was 0.97 (95% confidence interval 0.77 1.20). 59 thromboembolic were 30 incidence population, corresponding 1.97 (1.50 2.54) (5.6 17.0) excess per 100 000 vaccinations. A higher than rate cerebral thrombosis observed: 20.25 (8.14 41.73); an 2.5 (0.9 5.2) any disorders 1.52 (0.97 2.25) 1.23 1.55). 15 deaths expected. Conclusions recipients increased including thrombosis, observed. For remaining safety outcomes, results largely reassuring, slightly bleeding, which could be influenced by surveillance recipients. absolute risks were, however, small, findings should interpreted light proven beneficial effects vaccine, context given country, limitations generalisability study findings.